Literature DB >> 12524141

Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes.

Nobuyuki Yasuda1, Takashi Inoue, Tatsuo Horizoe, Kaya Nagata, Hiroe Minami, Tsutomu Kawata, Yorihisa Hoshino, Hitoshi Harada, Seiji Yoshikawa, Osamu Asano, Junsaku Nagaoka, Manabu Murakami, Shinya Abe, Seiichi Kobayashi, Isao Tanaka.   

Abstract

The adenosine receptor subtype mediating glucose production by glycogenolysis and gluconeogenesis was studied in primary cultured rat hepatocytes. Adenosine and adenosine agonists caused cyclic AMP accumulation in rat hepatocytes. The order of potency was 5'-N-ethylcarboxamidoadenosine (NECA)>R(-)-N(6)-(2-phenylisopropyl)adenosine (RPIA)>adenosine>2-[p-(carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680). Furthermore, adenosine agonists stimulated glycogenolysis and gluconeogenesis. The order of potency was NECA>RPIA>CGS21680. The rank order of potency is typical for adenosine A(2B) receptors. Glycogenolysis stimulated by NECA was fully inhibited by nonselective adenosine antagonists, 9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS15943). However, the adenosine A(2A) receptor-selective antagonist, 8-(3-chlorostyryl)caffeine (CSC), and the adenosine A(1) receptor-selective antagonist, (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-alpha]pyridin-3-yl)acryloyl]-2-piperidine ethanol (FK453), had a low inhibitory potency. A strong correlation was found between the inhibitory effect of adenosine antagonists on NECA-induced glucose production and that on intracellular cyclic AMP generation in rat hepatocytes. Our results suggest that adenosine stimulates cyclic AMP formation and regulates glycogenolysis and gluconeogenesis, most likely through the adenosine A(2B) receptor subtype in rat hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524141     DOI: 10.1016/s0014-2999(02)02832-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

Review 1.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

Review 2.  Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.

Authors:  Luca Antonioli; Corrado Blandizzi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 3.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

4.  Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.

Authors:  Chaonan Ye; Kun Han; Jinxiu Lei; Kui Zeng; Su Zeng; Haixing Ju; Lushan Yu
Journal:  Br J Pharmacol       Date:  2018-10-04       Impact factor: 8.739

5.  Coronary artery disease: a study on the joint role of birth weight, adenosine deaminase, and gender.

Authors:  F Gloria-Bottini; M Banci; P Saccucci; N Lucarini; F Ianniello; G Paradisi; A Magrini; E Bottini
Journal:  Cardiol Res Pract       Date:  2010-04-13       Impact factor: 1.866

6.  Caffeine modifies blood glucose availability during prolonged low-intensity exercise in individuals with type-2 diabetes.

Authors:  Luiz Augusto da Silva; Leandro de Freitas; Thiago Emannuel Medeiros; Raul Osiecki; Renan Garcia Michel; André Luiz Snak; Carlos Ricardo Maneck Malfatti
Journal:  Colomb Med (Cali)       Date:  2014-06-30

7.  Adenosine, adenosine receptors and their role in glucose homeostasis and lipid metabolism.

Authors:  Milka Koupenova; Katya Ravid
Journal:  J Cell Physiol       Date:  2013-03-04       Impact factor: 6.384

8.  Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction.

Authors:  Stevan P Tofovic; Eman M Salah; Glenn J Smits; Eric T Whalley; Barry Ticho; Aaron Deykin; Edwin K Jackson
Journal:  J Pharmacol Exp Ther       Date:  2015-11-19       Impact factor: 4.030

Review 9.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

Review 10.  Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.

Authors:  Olakunle Sanni; G Terre'Blanche
Journal:  Rev Endocr Metab Disord       Date:  2021-06-24       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.